



OPEN
ENTREPRENEURSHIP

Apply to co-found no later than 16 November 2025
<https://open-entrepreneurship.com/cofounder/>

CO-FOUNDER NEEDED

Pioneering EA2-targeted medicines to achieve lasting remission in autoimmune disease.

SERENDO THERAPEUTICS

THE PROBLEM

Autoimmune diseases affect 300M+ people worldwide and are driven by aberrant activation of B- and T-cells. Most approved therapies blunt the immune system broadly—yielding incomplete control, safety risks, frequent flares, and lifelong treatment.

OUR SOLUTION

We are developing first-in-class small-molecule inhibitors of Endophilin A2 (EA2), a key regulator of B- and T-cell activation. By selectively dialing down this pathway, we aim to deliver deep, durable remission with a better safety profile than chronic broad immunosuppression.

PATENT STATUS

We have identified 5 patentable small molecules binding to EA2 with composition-of-matter and methods-of-use claims planned. Our IPR strategy is to wait until a lead candidate is nominated to maximize claim scope and global strategy.

FINANCIAL OVERVIEW

We are preclinical discovery (hit identification/validation) stage and aim to exit through acquisition after human Proof-of-concept. We have received 100kEUR in-kind non-dilutive support since start in 2025. Near-term raise is € 0.8M seed to complete the planned hit expansion and validation studies and reach a patentable lead candidate.

MILESTONES ACHIEVED

- Biological rationale consolidated: EA2 linked to pathological B- and T-cell activation;
- Screening & assay plan in place: HTS → orthogonal confirmation → counterscreens; clear hit criteria and triage rules.
- IP groundwork: FTO scan initiated; composition-of-matter + methods-of-use strategy
- Development roadmap: hit-to-lead and early DMPK/safety funnel to in-vivo PoC.

TARGET MARKET & CUSTOMERS

Our customers are mid/large pharma seeking first-in-class autoimmune assets. We aim for clinical PoC, then partner for late-stage development to deliver safer, oral, durable therapies to patients. The autoimmune therapeutics market exceeds \$230B annually and is growing rapidly.

CO-FOUNDER PROFILE WE ARE LOOKING FOR

Must-have qualifications/background

- Clinical and/or commercial experience in large pharma company
- Proven ability to design clinical development plans and translate target biology into staged PoC strategies.
- Willingness to lead investor outreach (intro meetings, follow-ups, data-room Q&A).
- Strong ownership mindset with a desire to build company value and share success.

Nice-to-have qualifications/background

- Capital raising experience (grants, angels, seed/Series A).
- Previous startup/biotech operating experience.
- Search & Evaluation (in-licensing diligence) from a pharma/BD role.
- M&A or licensing deal exposure (term sheets, diligence, negotiations).

Personal fit

We operate virtually with partners and collaborators, so you should be comfortable working remotely. We value a kind, collaborative culture where every voice is heard and respected. A good sense of humor and low-ego, team-first attitude are big pluses.

TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

Participate in investor meetings. Clinical strategy: outline the path to human proof-of-concept, including indication selection, endpoints, biomarkers, and an accelerated first-in-human plan.

ACADEMIC & ENTREPRENEURIAL BACKGROUND OF CURRENT CO-FOUNDERS

15+ years in early drug development across chronic inflammation and oncology. Former CEO of Omnio AB; raised €8M and advanced a first-in-class biologic from ideation to the start of regulatory engagement.

PHYSICAL ADDRESS

Norra kustvägen 20, Helsingborg, Sweden

READ MORE HERE

www.serendotx.com



ABOUT OPEN ENTREPRENEURSHIP

Open Entrepreneurship is a collaboration between all Danish universities aiming to create more research-based startups.

www.open-entrepreneurship.com



SUPPORTED BY

Uddannelses- og
Forskningsministeriet